Toronto-headquartered Ramm Pharma, an organization with medical hashish manufacturing operations in Uruguay, mentioned the Peruvian Ministry of Health authorised its Epifractán 5% CBD product “for sale in pharmacies throughout the country for various indications as prescribed by a medical doctor.”
The information underscores the restricted however rising Latin American intraregional medical hashish commerce, impartial from North American hashish manufacturing.
Ramm Pharma “entered into an agreement with CannFarm Peru S.A.C. to distribute its products throughout Peru,” the corporate mentioned in a information launch.
The solely different registered “cannabis-derived natural health product” – a class created by Peruvian rules – belongs to Canada-based Canopy Growth and likewise has CBD because the energetic ingredient.
Niklaus Schwenker, director of communications and technique for Canopy Growth Latin America, advised Marijuana Business Daily that Peru “has one of the most advanced regulations for cannabis in Latin America and is a priority for the Canopy Growth in the region.”
With product approval already in place, the corporate expects to “serve Peruvian patients in the near term while continuing its physician-education activities through the Spectrum Academy,” Schwenker mentioned.
Companies with registered merchandise should get hold of the required import permits to have the ability to obtain the shipments and distribute to pharmacies across the nation, Andres Vazquez Vargas, CEO of CannFarm Peru, advised MJBizDaily.
“After obtaining the import permit, we expect to receive the first shipment from Uruguay and start distributing to patients in Peru in the next weeks,” Vazquez mentioned.
The product to be imported by CannFarm is registered in Uruguay by the correspondent Ministry of Health and has been out there in pharmacies beneath prescription since 2018.
Ramm Pharma, the producer, has a Good Manufacturing Practice certification from the Uruguayan Ministry of Health.
The firm at the moment exports from Uruguay to neighboring nations, reminiscent of Brazil and Argentina, beneath “compassionate use” applications, which usually means the merchandise have to be shipped case-by-case to particular licensed sufferers.
As of July 10, the general public database of the Peruvian well being authority confirmed 17 product registrations had been submitted by six firms and had been pending approval.
This is in addition to Sativex, manufactured by GW Pharmaceuticals in the United Kingdom, which was authorised as a cannabis-derived pharmaceutical however remains to be not being commercialized, in line with native sources.
As of early July, solely a CBD product was out there for sufferers in Peru, and it’s offered by the Peruvian General Directorate of Medicines, Supplies and Drugs (DIGEMID) in just one pharmacy in the nation. That pharmacy is run by the well being company.
That product was purchased by the nation well being authority by way of two totally different provide tenders.
Alfredo Pascual could be reached at [email protected]